J.P. Morgan isn't giving up on GenMark Diagnostics (GNMK -12.2%) despite the shares' ~35% decline since June 10. Analyst Tycho Peterson acknowledges the company's tepid guidance, but maintains an Overweight rating on the stock. PT lowered to $15 from $17.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs